PE20121093A1 - Combinacion farmaceutica que comprende un inhibidor de mek y un inhibidor de b-raf - Google Patents

Combinacion farmaceutica que comprende un inhibidor de mek y un inhibidor de b-raf

Info

Publication number
PE20121093A1
PE20121093A1 PE2012000502A PE2012000502A PE20121093A1 PE 20121093 A1 PE20121093 A1 PE 20121093A1 PE 2012000502 A PE2012000502 A PE 2012000502A PE 2012000502 A PE2012000502 A PE 2012000502A PE 20121093 A1 PE20121093 A1 PE 20121093A1
Authority
PE
Peru
Prior art keywords
inhibitor
combination including
pharmaceutical combination
raf
phenyl
Prior art date
Application number
PE2012000502A
Other languages
English (en)
Inventor
Sylvie Laquerre
Melissa Dumble
Peter F Lebowitz
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PE20121093A1 publication Critical patent/PE20121093A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

REFERIDA A UNA COMBINACION QUE COMPRENDE UN INHIBIDOR DE MEK TAL COMO N-{3-[3-CICLOPROPIL-5-(2-FLUORO-4-YODO-FENIL-AMINO)-6,8-DIMETILO-2,4,7-TRIOXO-3,4,6,7-TETRAHIDRO-2H-PIRIDO-[4,3-d]-PIRIMIDIN-1-IL]-FENIL}-ACETAMIDA (FORMULA I) CON UN INHIBIDOR DE B-Raf TAL COMO N-{3-[5-(2-AMINO-4-PIRIMIDINIL)-2-(1,1-DIMETIL-ETIL)-1,3-TIAZOL-4-IL]-2-FLUORO-FENIL}-2,6-DIFLUORO-BENCEN-SULFONAMIDA (FORMULA II). DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DEL CANCER
PE2012000502A 2009-10-16 2010-10-15 Combinacion farmaceutica que comprende un inhibidor de mek y un inhibidor de b-raf PE20121093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16

Publications (1)

Publication Number Publication Date
PE20121093A1 true PE20121093A1 (es) 2012-09-04

Family

ID=43876568

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000502A PE20121093A1 (es) 2009-10-16 2010-10-15 Combinacion farmaceutica que comprende un inhibidor de mek y un inhibidor de b-raf

Country Status (34)

Country Link
US (3) US8703781B2 (es)
EP (4) EP4397376A2 (es)
JP (1) JP5718929B2 (es)
KR (1) KR101729116B1 (es)
CN (1) CN102655753B (es)
AU (1) AU2010306653B2 (es)
BR (1) BR112012008854B8 (es)
CA (1) CA2775803C (es)
CL (1) CL2012000964A1 (es)
CO (1) CO6531498A2 (es)
CR (1) CR20120155A (es)
CY (1) CY1122013T1 (es)
DK (3) DK3560498T3 (es)
DO (1) DOP2012000091A (es)
EA (1) EA020589B1 (es)
ES (2) ES2745479T3 (es)
FI (1) FI4159217T3 (es)
HR (2) HRP20221304T1 (es)
HU (2) HUE060206T2 (es)
IL (1) IL219073A (es)
LT (2) LT3560498T (es)
MA (1) MA33746B1 (es)
ME (1) ME03497B (es)
MX (1) MX2012004413A (es)
MY (1) MY174759A (es)
NZ (1) NZ598913A (es)
PE (1) PE20121093A1 (es)
PL (2) PL2488033T3 (es)
PT (2) PT2488033T (es)
RS (2) RS63702B1 (es)
SI (1) SI2488033T1 (es)
UA (1) UA105064C2 (es)
WO (1) WO2011047238A1 (es)
ZA (1) ZA201202612B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
CA2962524C (en) 2008-06-16 2020-07-14 University Of Tennessee Research Foundation (2-(1-h-indolyl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone useful for the treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
MX343368B (es) 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2013096430A1 (en) * 2011-12-22 2013-06-27 Glaxosmithkline Llc Method of treating cancer with magea3 immunotherapeutic with braf inhibitor and/or mek inhibitor
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
DK2892535T3 (da) * 2012-09-04 2022-01-03 Novartis Ag Fremgangsmåde til adjuverende cancerbehandling
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
PL2925299T3 (pl) * 2012-11-30 2018-11-30 Novartis Ag Nowa kompozycja farmaceutyczna
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
KR102246652B1 (ko) 2013-03-05 2021-04-29 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
MA38643A1 (fr) * 2013-06-03 2017-10-31 Novartis Ag Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
EP3079698A1 (en) * 2013-12-12 2016-10-19 Novartis AG Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
ES2815374T3 (es) 2014-05-06 2021-03-29 Oncternal Therapeutics Inc Compuestos para el tratamiento del cáncer
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CA3042697A1 (en) * 2016-11-03 2018-05-11 The Regents Of The University Of Michigan Small molecule dual inhibitors of egfr/pi3k and uses thereof
CN112867803A (zh) 2018-10-16 2021-05-28 诺华股份有限公司 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN112294965B (zh) * 2019-07-26 2023-03-14 苏州亚盛药业有限公司 Mdm2抑制剂的药物组合物及其在预防和/或治疗疾病中的用途
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANCER IN DOGS
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
JP2024511373A (ja) 2021-03-18 2024-03-13 ノバルティス アーゲー がんのためのバイオマーカーおよびその使用
AU2022381730A1 (en) * 2021-11-02 2024-05-02 Verastem, Inc. Methods of treating abnormal cell growth
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
NZ518032A (en) * 1999-11-22 2004-02-27 Smithkline Beecham Plc Substituted imidazole derivatives
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
EP2175885B1 (en) 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
EA020589B1 (ru) 2014-12-30
IL219073A (en) 2016-05-31
DK2488033T3 (da) 2019-09-02
FI4159217T3 (fi) 2024-08-15
UA105064C2 (uk) 2014-04-10
LT3560498T (lt) 2022-11-25
MA33746B1 (fr) 2012-11-01
PL2488033T3 (pl) 2019-12-31
AU2010306653A1 (en) 2012-05-10
EP3560498A1 (en) 2019-10-30
EA201290149A1 (ru) 2012-11-30
CO6531498A2 (es) 2012-09-28
CL2012000964A1 (es) 2012-08-31
RS59181B1 (sr) 2019-10-31
DOP2012000091A (es) 2013-09-15
CN102655753B (zh) 2015-11-25
ES2745479T3 (es) 2020-03-02
ZA201202612B (en) 2013-09-25
AU2010306653B2 (en) 2013-10-24
SI2488033T1 (sl) 2019-10-30
ME03497B (me) 2020-04-20
HUE046139T2 (hu) 2020-02-28
HUE060206T2 (hu) 2023-02-28
EP2488033A1 (en) 2012-08-22
CN102655753A (zh) 2012-09-05
BR112012008854B1 (pt) 2020-12-29
US20140187566A1 (en) 2014-07-03
HRP20221304T1 (hr) 2022-12-23
KR101729116B1 (ko) 2017-05-02
BR112012008854B8 (pt) 2021-05-25
CA2775803C (en) 2017-11-21
MY174759A (en) 2020-05-13
PT2488033T (pt) 2019-09-10
IL219073A0 (en) 2012-06-28
US8703781B2 (en) 2014-04-22
DK3560498T3 (da) 2022-11-14
DK4159217T3 (da) 2024-08-12
MX2012004413A (es) 2012-05-08
BR112012008854A2 (pt) 2015-09-22
EP2488033B1 (en) 2019-06-12
CA2775803A1 (en) 2011-04-21
CR20120155A (es) 2012-07-05
PT3560498T (pt) 2022-11-03
KR20120104547A (ko) 2012-09-21
US8952018B2 (en) 2015-02-10
NZ598913A (en) 2013-11-29
RS63702B1 (sr) 2022-11-30
LT2488033T (lt) 2019-09-10
JP5718929B2 (ja) 2015-05-13
EP4397376A2 (en) 2024-07-10
EP2488033A4 (en) 2014-04-30
PL3560498T3 (pl) 2022-12-12
CY1122013T1 (el) 2020-10-14
WO2011047238A1 (en) 2011-04-21
HRP20191617T1 (hr) 2019-12-13
ES2930157T3 (es) 2022-12-07
JP2013508294A (ja) 2013-03-07
EP4159217A1 (en) 2023-04-05
EP3560498B1 (en) 2022-08-17
US20120196879A1 (en) 2012-08-02
EP4159217B1 (en) 2024-05-22
US20150111904A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
PE20121093A1 (es) Combinacion farmaceutica que comprende un inhibidor de mek y un inhibidor de b-raf
AR091259A1 (es) Formas solidas de un compuesto antiviral
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CR9398S (es) Contenedor
CR9399S (es) Contenedor
CR20140378A (es) Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
CR9611S (es) Contenedor
PE20211094A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
ECSP12012041A (es) Dispositivo
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
CL2011003022A1 (es) Compuestos derivados de 2,4 diaminopirimidina, inhibidores de quinasa ptk2; composicion farmaceutica que comprende a uno de los compuestos, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva, tal como cancer.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2013002688A1 (es) Compuestos derivados de 1,4-diazabiciclo[3,2,2]-nonano, quinuclidina, 1-azabiciclo[2,2,2]-octilo sustituidas; y uso como inhibidores de glucosilceramida sintasa, utiles en el tratamiento de enfermedades metabolicas, tales como almacenamiento lisosomico, solo en combinacion con terapia de reemplazo enzimatico y para el tratamiento del cancer.
CR20110339A (es) Compuestos útiles para inhibir chk1
CL2013000378A1 (es) Combinacion farmaceutica que comprende un farmaco antipsicotico atipico, tal como risperidona y olanzapina, entre otros, y un compuesto derivado de piperazina-fenil-metanona, antagonista del receptor de glyt1; método de tratamiento; y su uso para el tratamiento de sintomas positivos y negativos de la esquizofrenia.
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
UA108711C2 (uk) Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
CR20110093A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
CR9619S (es) Contenedor y cierre
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico

Legal Events

Date Code Title Description
FG Grant, registration